消息面上，11月6日晚，兆科眼科宣布，公司已与印度尼西亚领先制药公司PT Ferron Par Pharmaceuticals （"PT Ferron"），就公司核心产品之一、用于治疗老花眼的创新药物BRIMOCHOL™ PF，签订了一份 针对印度尼西亚市场的分销和供应协议。该药物授权引进自Tenpoint Therapeutics, Ltd.。根据协议条 款，兆科眼科授予PT Ferron在印度尼西亚进口、推广、分销、营销和销售该产品的独家权利。兆科眼 科将获得一笔预付款项，并可根据若干成就获得额外的里程碑付款。 此外，兆科眼科的合作伙伴、BRIMOCHOL™ PF的研发者Tenpoint Therapeutics于2025年6月公布，美国 食品药品管理局已经接受了该药物的新药上市申请，并将《处方药使用者付费法案》（"PDUFA"）日 期定于2026年1月28日。 智通财经APP获悉，兆科眼科-B(06622)涨超7%，截至发稿，涨7.64%，报3.38港元，成交额238.93万港 元。 ...

Group 1 - The company has entered into a distribution and supply agreement with PT Ferron Par Pharmaceuticals for the commercialization of BRIMOCHOL™ PF in Indonesia, granting PT Ferron exclusive rights for import, promotion, distribution, marketing, and sales of the product [1] - The company will receive an upfront payment and may earn additional milestone payments based on specific achievements [1] - The developer of BRIMOCHOL™ PF, Tenpoint Therapeutics, announced that the FDA has accepted the new drug application for the product, with a review deadline set for January 28, 2026 [1] Group 2 - BRIMOCHOL™ PF is a preservative-free, experimental eye drop intended to correct near vision loss due to aging, and is part of a multi-center, randomized, double-blind study involving 629 participants across 47 trial centers in the U.S. [2] - The study compares the safety and efficacy of BRIMOCHOL™ PF with other treatments for presbyopia [2] Group 3 - PT Ferron Par Pharmaceuticals, a member of the Dexa Group, has been operating since 2001 and is one of the top 15 largest pharmaceutical companies in Indonesia according to IQVIA data [3] - The company has received recognition from regulatory agencies in the UK and Portugal, enhancing its market influence and operational capabilities through a diverse product portfolio and strong strategic partnerships [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Zhaoke Ophthalmology Limited 關於老花眼 （於英屬處女群島註冊成立並於開曼群島存續的有限公司） 兆科眼科有限公司 （股份代號：6622） 自 願 性 公 佈－就 於 印 度 尼 西 亞 商 業 化BRIMOCHOL™ PF 與PT FERRON訂立分銷協議 本 公 告 乃 由 兆 科 眼 科 有 限 公 司（「本公司」）董 事 會（「董事會」）自 願 作 出。 本 公 司 董 事 會 欣 然 宣 佈，本 公 司 與 領 先 印 度 尼 西 亞 製 藥 公 司PT Ferron Par Pharmaceuticals（「PT Ferron」）就 於 印 度 尼 西 亞 商 業 化BRIMOCHOL™ PF（由Tenpoint Therapeutics, Ltd.（「Tenpoint」）授 出 許 可 權 的 創 新 藥，用 ...

今年，港股创新药势不可挡，成为资本市场的重磅热点。 数据最具说服力，港股创新药概念指数从年初至今涨幅已超100%，不仅大幅跑赢恒生指数，更以扎实 的上涨态势重塑了市场对创新药产业的信心。 这轮行情的背后并非偶然，机构普遍认为，其核心驱动力是政策、基本面、资金面的三重共振，而非短 期利好的临时拉动。譬如，7月国家医保局首次将具备高临床价值但暂未纳入医保的创新药纳入商保支 付范围，为创新药开辟了更多元的变现路径；产业端的出海进程也取得历史性突破，大额BD合作频频 落地，整个创新药产业的活力正加速释放。 在行业整体向好的背景下，基金经理对下半年行情的预判也更为积极，更明确指出当前正是中长期布局 创新药板块的重要窗口期。例如，永赢医药创新智选基金经理储可凡与单林便一致认为，创新药是当前 医药领域确定性最强、置信度最高、增长空间最大的核心板块。随着国内企业持续产出优秀临床数据， 叠加出海能力不断强化，未来商业化兑现路径将愈发清晰，业绩落地节奏也会逐步加快，长期成长逻辑 坚实。 正是在这样的产业红利期，近日，眼科创新药企兆科眼科发布2025年中期财报，阿托品滴眼液、环孢素 A眼凝胶、贝伐单抗注射液三大重磅眼药均已提交上市 ...

Core Viewpoint - Zhaoke Ophthalmology-B (06622) reported a significant decline in revenue and an increase in net loss for the first half of 2025, leading to a drop in stock price by over 8% [1] Financial Performance - The company achieved revenue of 15.803 million HKD, representing a year-on-year decrease of 68.25% [1] - The net loss amounted to 117 million HKD, which is an increase of 53.85% compared to the previous period [1] Reasons for Financial Changes - The increase in net loss is primarily attributed to the absence of one-time licensing income recognized in the previous period under a product licensing agreement [1] - Increased R&D expenses due to the initiation of Phase I and II clinical trials for BRIMOCHOL™ PF and CARBACHOL™ PF, as well as a new Phase III clinical trial for cyclosporine eye gel, offset the impact of a continuous reduction in administrative expenses during the reporting period [1]

Core Viewpoint - The company reported a significant decline in revenue and an increase in net loss for the six months ending June 30, 2025, primarily due to changes in sales strategy and increased R&D expenses [1] Financial Performance - Revenue for the period was 15.803 million, representing a year-on-year decrease of 68.25% [1] - The net loss amounted to 117 million, which is an increase of 53.85% compared to the previous period [1] Reasons for Performance Changes - The increase in net loss was mainly attributed to the absence of one-time licensing income recognized in the previous period under a product licensing agreement [1] - Increased R&D expenses were driven by the initiation of Phase I and II clinical trials for BRIMOCHOL™ PF and CARBACHOL™ PF, as well as a new round of Phase III clinical trials for cyclosporine eye gel [1] - The decrease in revenue was a result of the company's shift in sales strategy, focusing on expanding the distribution network for ophthalmic drugs and restructuring the sales team to concentrate on key sales regions [1]